Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980942 | 0.86 | PPARG (0.41) | CYP2D6CES2CES1ALDH1A1CYP3A4 | |
| SCHEMBL3458611 | 0.84 | EPHX1 (0.43) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL22758109 | 0.77 | ALDH1A1 (0.42) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL3154551 | 0.77 | EPHX1 (0.38) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL5892872 | 0.75 | ALDH1A1 (0.40) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL11825339 | 0.73 | EPHX1 (0.41) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL5550527 | 0.72 | CYP2D6 (0.46) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL1068632 | 0.71 | KMT2A (0.57) | SMN1; SMN2CYP2D6CYP1A2PKMNPSR1 | |
| SCHEMBL17491377 | 0.71 | SMN1; SMN2 (0.48) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM | |
| SCHEMBL19615169 | 0.71 | SMN1; SMN2 (0.44) | EPHX1SMN1; SMN2CYP2D6CYP1A2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645784-B2 | Benzimidazole derivatives | ASTRAZENECA AB (SE) | 2010-01-12 | — | — | US | disclosed |
| US-20060287377-A1 | New benzimidazole derivatives | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287377-A1 | New benzimidazole derivatives | CYP2C9, CDK9, CCNI | EPHX1 3998/4885SMN1; SMN2 2297/4885CYP2D6 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.